Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9812045 | 0.82 | CYP2A6 (0.58) | CYP2A6APPLOXL2NPC1MAPT | |
| SCHEMBL1706926 | 0.79 | CYP2A6 (0.64) | CYP2A6APPLOXL2NPC1MAPT | |
| SCHEMBL15095310 | 0.76 | CYP2A6 (0.60) | CYP2A6APPLOXL2NPC1MAPT | |
| SCHEMBL25508775 | 0.76 | CYP2A6 (0.60) | CYP2A6APPLOXL2NPC1MAPT | |
| SCHEMBL17185672 | 0.75 | CYP2A6 (0.64) | CYP2A6APPLOXL2NPC1MAPT | |
| SCHEMBL9956377 | 0.75 | CYP2A6 (1.00) | CYP2A6APPLOXL2NPC1MAPT | |
| SCHEMBL225144 | 0.75 | CYP2A6 (0.64) | CYP2A6APPLOXL2NPC1MAPT | |
| SCHEMBL11396362 | 0.75 | CYP2A6 (0.64) | CYP2A6APPLOXL2NPC1MAPT | |
| SCHEMBL91009 | 0.75 | CYP2A6 (1.00) | CYP2A6APPLOXL2NPC1MAPT | |
| SCHEMBL2900756 | 0.75 | CYP2A6 (0.64) | CYP2A6APPLOXL2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126987-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-09-08 | — | — | US | disclosed |
| EP-2091948-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2091948-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20080214620-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008065141-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-06-05 | — | — | WO | disclosed |
| US-20070173532-A1 | New Piperidine Antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-26 | — | — | US | disclosed |
| EP-1799674-A1 | NEW PIPERIDINE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038172-A1 | NEW PIPERIDINE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1323726-A1 | ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1167375-A1 | ERYTHROMYCIN DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | MAPRE1, MAPRE2, MRPS27 | CYP2A6 1920/4885APP 4882/4885LOXL2 1938/4885 |
| US-20080214620-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, GLUL | CYP2A6 3719/4885APP 3363/4885LOXL2 3398/4885 |
| US-20070173532-A1 | New Piperidine Antibiotics | OPRM1, SIGMAR1, CBR3 | CYP2A6 2393/4885APP 4733/4885LOXL2 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.